1. Clinical utility of liver fat quantification for determining cardiovascular disease risk among patients with type 2 diabetes
- Author
-
Kuo, Selena Z, Cepin, Sandra, Bergstrom, Jaclyn, Siddiqi, Harris, Jung, Jinho, Lopez, Scarlett, Huang, Daniel Q, Taub, Pam, Amangurbanova, Maral, and Loomba, Rohit
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Biomedical Imaging ,Prevention ,Aging ,Obesity ,Digestive Diseases ,Heart Disease ,Liver Disease ,Cardiovascular ,Clinical Research ,Diabetes ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,Metabolic and endocrine ,Good Health and Well Being ,Adult ,Humans ,Female ,Male ,Diabetes Mellitus ,Type 2 ,Cross-Sectional Studies ,Prospective Studies ,Cardiovascular Diseases ,Liver ,Non-alcoholic Fatty Liver Disease ,Magnetic Resonance Imaging ,cardiovascular disease risk ,diabetes ,nonalcoholic fatty liver disease ,non-invasive imaging ,Pharmacology and Pharmaceutical Sciences ,Gastroenterology & Hepatology ,Clinical sciences ,Pharmacology and pharmaceutical sciences - Abstract
BackgroundNonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are independent risk factors for cardiovascular disease (CVD).AimsTo examine the clinical utility of liver fat quantification for determining CVD risk among a well-phenotyped cohort of patients with T2DM.MethodsThis was a cross-sectional analysis of a prospective cohort of adults aged ≥50 with T2DM. Liver fat was quantified with magnetic resonance imaging proton-density-fat-fraction (MRI-PDFF), an advanced imaging-based biomarker. Patients were stratified into a higher liver fat group (MRI-PDFF ≥ 14.6%), and a lower liver fat group (MRI-PDFF
- Published
- 2023